NASDAQ
BLRX

BioLineRx Ltd

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

BioLineRx Ltd Stock Price

Vitals

Today's Low:
$1.79
Today's High:
$2.1
Open Price:
$1.97
52W Low:
$0.55
52W High:
$1.98
Prev. Close:
$2.03
Volume:
3032588

Company Statistics

Market Cap.:
$96.66 million
Book Value:
0.63
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-27.83%
Return on Equity TTM:
-62.78%

Company Profile

BioLineRx Ltd had its IPO on 2011-07-25 under the ticker symbol BLRX.

The company operates in the Healthcare sector and Biotechnology industry. BioLineRx Ltd has a staff strength of 49 employees.

Stock update

Shares of BioLineRx Ltd opened at $1.97 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.79 - $2.1, and closed at $1.99.

This is a -1.97% slip from the previous day's closing price.

A total volume of 3,032,588 shares were traded at the close of the day’s session.

In the last one week, shares of BioLineRx Ltd have slipped by -1.49%.

BioLineRx Ltd's Key Ratios

BioLineRx Ltd has a market cap of $96.66 million, indicating a price to book ratio of 0.7645 and a price to sales ratio of 0.

In the last 12-months BioLineRx Ltd’s revenue was $0 with a gross profit of $0 and an EBITDA of $-31463000. The EBITDA ratio measures BioLineRx Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, BioLineRx Ltd’s operating margin was 0% while its return on assets stood at -27.83% with a return of equity of -62.78%.

In Q1, BioLineRx Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

BioLineRx Ltd’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0.2

Its diluted EPS in the last 12-months stands at $-0.48 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0.2. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into BioLineRx Ltd’s profitability.

BioLineRx Ltd stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.0704. Its price to sales ratio in the trailing 12-months stood at 0.

BioLineRx Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$68.65 million
Total Liabilities
$12.04 million
Operating Cash Flow
$0
Capital Expenditure
$129000
Dividend Payout Ratio
0%

BioLineRx Ltd ended 2024 with $68.65 million in total assets and $0 in total liabilities. Its intangible assets were valued at $68.65 million while shareholder equity stood at $39.11 million.

BioLineRx Ltd ended 2024 with $0 in deferred long-term liabilities, $12.04 million in other current liabilities, 27100000.00 in common stock, $-342154000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $9.07 million and cash and short-term investments were $43.29 million. The company’s total short-term debt was $2,937,000 while long-term debt stood at $8.24 million.

BioLineRx Ltd’s total current assets stands at $44.33 million while long-term investments were $0 and short-term investments were $34.22 million. Its net receivables were $302000.00 compared to accounts payable of $7.14 million and inventory worth $0.

In 2024, BioLineRx Ltd's operating cash flow was $0 while its capital expenditure stood at $129000.

Comparatively, BioLineRx Ltd paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$1.99
52-Week High
$1.98
52-Week Low
$0.55
Analyst Target Price
$9.67

BioLineRx Ltd stock is currently trading at $1.99 per share. It touched a 52-week high of $1.98 and a 52-week low of $1.98. Analysts tracking the stock have a 12-month average target price of $9.67.

Its 50-day moving average was $1.6 and 200-day moving average was $1.12 The short ratio stood at 3.2 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 1089% are held by institutions.

Frequently Asked Questions About BioLineRx Ltd

The stock symbol (also called stock or share ticker) of BioLineRx Ltd is BLRX

The IPO of BioLineRx Ltd took place on 2011-07-25

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$67.62
-0.88
-1.28%
$430.35
-16.6
-3.71%
$1166.05
-18.35
-1.55%
$10.73
0.09
+0.85%
$5.8
-0.1
-1.69%
$2.12
0.01
+0.47%
Nova Ltd (NVMI)
$117.08
-0.96
-0.81%
$42.32
-1.68
-3.82%
Transcat Inc (TRNS)
$111.94
-0.11
-0.1%
$166.92
-3.6
-2.11%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi’in, Israel.

Address

Modi?in Technology Park, Hevel Modi'in, Israel, 7177871